Yigla Mordechai, Nakhoul Farid, Sabag Anat, Tov Naveh, Gorevich Bella, Abassi Ziad, Reisner Shimon A
Division of Pulmonary Medicine, Rambam Medical Center and Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
Chest. 2003 May;123(5):1577-82. doi: 10.1378/chest.123.5.1577.
The aims of this study were to evaluate the incidence of unexplained pulmonary hypertension (PH) among patients with end-stage renal disease (ESRD) and to suggest possible etiologic factors.
The incidence of PH was prospectively estimated by Doppler echocardiography in 58 patients with ESRD receiving long-term hemodialysis via arteriovenous access, and in control groups of 5 patients receiving peritoneal dialysis (PD) and 12 predialysis patients without a known other cause to suggest the presence of PH. Clinical variables were compared between patients with and without PH receiving hemodialysis. Changes in pulmonary artery pressure (PAP) values before and after onset of hemodialysis via arteriovenous access, arteriovenous access compression, and successful kidney transplantation were recorded.
PH > 35 mm Hg was found in 39.7% of patients receiving hemodialysis (mean +/- SD, 44 +/- 7 mm Hg; range, 37 to 65 mm Hg), in none of the patients receiving PD, and in 1 of 12 predialysis patients. Patients with PH receiving hemodialysis had a significantly higher cardiac output (6.9 L/min vs 5.5 L/min, p = 0.017). PH developed in four of six patients with normal PAP after onset of hemodialysis therapy via arteriovenous access. One-minute arteriovenous access compression in four patients decreased the mean systolic PAP from 52 +/- 7 to 41 +/- 4 mm Hg (p = 0.024). PH normalized in four of five patients receiving hemodialysis following kidney transplantation. Kaplan-Meier survival analysis according to PAP values revealed significant survival differences (p < 0.024).
This study demonstrates a surprisingly high incidence of PH among patients with ESRD receiving long-term hemodialysis with surgical arteriovenous access. Both ESRD and long-term hemodialysis via arteriovenous access may be involved in the pathogenesis of PH by affecting pulmonary vascular resistance and cardiac output.
本研究旨在评估终末期肾病(ESRD)患者中不明原因肺动脉高压(PH)的发生率,并提出可能的病因。
通过多普勒超声心动图前瞻性评估58例接受动静脉通路长期血液透析的ESRD患者、5例接受腹膜透析(PD)的患者以及12例无其他已知病因提示存在PH的透析前患者中PH的发生率。比较接受血液透析的有PH和无PH患者的临床变量。记录动静脉通路血液透析开始前后、动静脉通路压迫以及成功肾移植前后肺动脉压(PAP)值的变化。
接受血液透析的患者中39.7%存在PH>35 mmHg(平均±标准差,44±7 mmHg;范围,37至65 mmHg),接受PD的患者中未发现PH,12例透析前患者中有1例存在PH。接受血液透析的PH患者心输出量显著更高(6.9 L/min对5.5 L/min,p = 0.017)。动静脉通路血液透析治疗开始后,6例PAP正常的患者中有4例出现了PH。4例患者进行1分钟动静脉通路压迫后,平均收缩期PAP从52±7降至41±4 mmHg(p = 0.024)。5例接受血液透析的患者中有4例在肾移植后PH恢复正常。根据PAP值进行的Kaplan-Meier生存分析显示存在显著的生存差异(p < 0.024)。
本研究表明,接受手术动静脉通路长期血液透析的ESRD患者中PH的发生率高得出奇。ESRD和通过动静脉通路进行的长期血液透析可能通过影响肺血管阻力和心输出量参与PH的发病机制。